Editorial & Opinion
Comment - Louis XIV's terminal illness clinical chronology favors necrotizing soft-tissue infection.
| Τίτλος: | Comment - Louis XIV's terminal illness clinical chronology favors necrotizing soft-tissue infection. |
|---|---|
| Συγγραφείς: | Demas A; ARGOS (Arts, Research and Gestures Observed Scientifically) Neurosciences and Arts, 229 rue Saint-Honoré, Paris, 75001, France. dr.alexisdemas@gmail.com. |
| Πηγή: | BMC nephrology [BMC Nephrol] 2026 Sep 02; Vol. 27 (1). Date of Electronic Publication: 2026 Sep 02. |
| Τύπος έκδοσης: | Letter |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369 (Electronic) Linking ISSN: 14712369 NLM ISO Abbreviation: BMC Nephrol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BioMed Central, [2000- |
| Ιατρικοί όροι (MeSH): | Calciphylaxis*/diagnosis , Diabetic Foot*/complications , Soft Tissue Infections*/diagnosis , Terminally Ill*, Humans ; Necrosis ; Famous Persons |
| Περίληψη: | Louis XIV's rapidly progressive terminal illness may be better explained by necrotizing soft-tissue infection than primary calciphylaxis. Severe distal pain, ascending gangrene, and fatal sepsis within three weeks suggest fulminant infection, plausibly arising from a diabetic foot lesion. Clinical chronology should remain central when evaluating competing retrospective clinicopathological hypotheses. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Ethical approval: Not applicable. Patient consent: Not applicable. Financial disclosures for the previous 12 months: None. The author declare that there are no additional disclosures to report. The author confirms that the approval of an institutional review board was not required for this work. Competing interests: The authors declare no competing interests. |
| References: | Ann Pharm Fr. 2026 Jun;84(4):553-555. (PMID: 42034285) N Engl J Med. 2017 Dec 7;377(23):2253-2265. (PMID: 29211672) BMC Nephrol. 2026 May 25;27(1):. (PMID: 42186010) Anaerobe. 2012 Apr;18(2):254-9. (PMID: 22120198) Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280. (PMID: 32176444) |
| Entry Date(s): | Date Created: 20260903 Date Completed: 20260903 Latest Revision: 20260908 |
| Update Code: | 20260908 |
| PubMed Central ID: | PMC13539707 |
| DOI: | 10.1186/s12882-026-05328-8 |
| PMID: | 42687157 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1471-2369 |
|---|---|
| DOI: | 10.1186/s12882-026-05328-8 |